Toxicology of the retina: Advances in understanding the defence mechanisms and pathogenesis of drug- and light-induced retinopathy

Clinical and Experimental Ophthalmology

Volumn 36, Issue 2, 2008, Pages 176-185

  Siu, Timothy L ^a   Morley, John W ^a,b   Coroneo, Minas T ^c  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b UNIVERSITY OF WESTERN SYDNEY   (Australia)

^c PRINCE OF WALES HOSPITAL   (Australia)

Author keywords

Cellular neurobiology; Molecular biology; Pharmacogenetics; Phototoxicity; Retina; Toxicology

Indexed keywords

ALLOPURINOL; AMIODARONE; ANTIARRHYTHMIC AGENT; ANTIBIOTIC AGENT; ANTIDEPRESSANT AGENT; ANTIMALARIAL AGENT; ANTINEOPLASTIC AGENT; ANTIOXIDANT; CARMUSTINE; CHLORPROMAZINE; DIAZEPAM; DIURETIC AGENT; FLUPHENAZINE; FUROSEMIDE; HYDROCHLOROTHIAZIDE; INDOMETACIN; MANNITOL; METHOTREXATE; NEUROLEPTIC AGENT; ORAL CONTRACEPTIVE AGENT; PHENOTHIAZINE; PHENYLPROPANOLAMINE; PLACEBO; PORPHYRIN; PSYCHOTROPIC AGENT; TETRACYCLINE; THIORIDAZINE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; WARFARIN;

ANTIOXIDANT ACTIVITY; APOPTOSIS; ARTERY OCCLUSION; BLOOD RETINA BARRIER; BLUE LIGHT; BRAIN TUMOR; CAPILLARY LEAK SYNDROME; CIGARETTE SMOKING; CLINICAL TRIAL; DEFENSE MECHANISM; DRUG STRUCTURE; GLIOBLASTOMA; HUMAN; LENS IMPLANT; LIGHT EXPOSURE; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PHOTORECEPTOR; PHOTOTHERAPY; PHOTOTOXICITY; PIGMENT EPITHELIUM; RETINA CAPILLARY; RETINA DEGENERATION; RETINA HEMORRHAGE; RETINA INJURY; RETINA MACULA AGE RELATED DEGENERATION; RETINA MACULOPATHY; RETINOPATHY; RETINOTOXICITY; REVIEW; SEASONAL AFFECTIVE DISORDER; SIDE EFFECT; THROMBOSIS; TIGHT JUNCTION; ULTRAVIOLET RADIATION; VISUAL ACUITY; VISUAL FIELD DEFECT;

ANIMALS; APOPTOSIS; BLOOD-RETINAL BARRIER; HUMANS; LIGHT; OXIDATIVE STRESS; RETINA; RETINAL DISEASES; RISK FACTORS; XENOBIOTICS;

EID: 41249086336     PISSN: 14426404     EISSN: 14429071     Source Type: Journal    
DOI: 10.1111/j.1442-9071.2008.01699.x     Document Type: Review

References (79)

1. Feke GT, Tagawa H, Deupree DM, Goger DG, Sebag J, Weiter JJ. Blood flow in the normal human retina. Invest Ophthalmol Vis Sci 1989; 30: 58-65.
2. Chiou GCY. Ophthalmic Toxicology, 2nd edn. Philadelphia, PA: Taylor & Francis, 1999.
3. Samardzija M, Wenzel A, Aufenberg S, Thiersch M, Reme C, Grimm C. Differential role of Jak-STAT signaling in retinal degenerations. FASEB J 2006; 20: 2411-13.
4. Ohta Y, Yamasaki T, Niwa T, Niimi K, Majima Y, Ishiguro I. Role of catalase in retinal antioxidant defence system: Its comparative study among rabbits, guinea pigs, and rats. Ophthalmic Res 1996; 28: 336-42.
5. Wenzel A, Grimm C, Samardzija M, Reme CE. Molecular mechanisms of light-induced photoreceptor apoptosis and neuroprotection for retinal degeneration. Prog Retinal Eye Res 2005; 24: 275-306.
6. Fraunfelder FT, Fraunfelder FW, Randall JA. Drug-Induced Ocular Side Effects, 5th edn. Boston, MA: Butterworth-Heinemann, 2001.
7. Grant WM, Schuman JS. Toxicology of the Eye. Effects on the Eyes and Visual System from Chemicals, Drugs, Metals and Minerals, Plants, Toxins, and Venoms: Also, Systemic Side Effects from Eye Medications, 4th edn. Springfield, IL: Thomas, 1993.
8. Cunha-Vaz JG. The blood-ocular barriers: Past, present, and future. Doc Ophthalmol 1997; 93: 149-57.
9. Tornquist P, Alm A, Bill A. Permeability of ocular vessels and transport across the blood-retinal barrier. Eye 1990; 4(Pt 2): 303-9.
10. Steuer H, Jaworski A, Elger B et al. Functional characterization and comparison of the outer blood-retina barrier and the blood-brain barrier. Invest Ophthalmol Vis Sci 2005; 46: 1047-53.
11. Tang VW, Goodenough DA. Paracellular ion channel at the tight junction. Biophys J 2003; 84: 1660-73.
12. Powell DW. Barrier function of epithelia. Am J Physiol 1981; 241: G275-88.
13. Huber JD, Egleton RD, Davis TP. Molecular physiology and pathophysiology of tight junctions in the blood-brain barrier. Trends Neurosci 2001; 24: 719-25.
14. Bok D. Processing and transport of retinoids by the retinal pigment epithelium. Eye 1990; 4(Pt 2): 326-32.
15. Scott JE. The chemical morphology of the vitreous. Eye 1992; 6(Pt 6): 553-5.
16. Moseley H, Foulds WS, Allan D, Kyle PM. Routes of clearance of radioactive water from the rabbit vitreous. Br J Ophthalmol 1984; 68: 145-51.
17. Butler JM, Unger WG, Grierson I. Recent experimental studies on the blood-aqueous barrier: The anatomical basis of the response to injury. Eye 1988; 2(Suppl.): S213-20.
18. Mausolf FA, Mensher JH. Experimental hyperviscosity retinopathy: preliminary report. Ann Ophthalmol 1973; 5: 205-9.
19. Gilmer G, Swartz M, Teske M, Crandall AS. Over-the-counter phenylpropanolamine: A possible cause of central retinal vein occlusion. Arch Ophthalmol 1986; 104: 642.
20. Kernan WN, Viscoli CM, Brass LM et al. Phenylpropanolamine and the risk of hemorrhagic stroke. N Engl J Med 2000; 343: 1826-32.
21. Shingleton BJ, Bienfang DC, Albert DM, Ensminger WD, Chandler WF, Greenberg HS. Ocular toxicity associated with high-dose carmustine. Arch Ophthalmol 1982; 100: 1766-72.
22. Miller DF, Bay JW, Lederman RJ, Purvis JD, Rogers LR, Tomsak RL. Ocular and orbital toxicity following intracarotid injection of BCNU (carmustine) and cisplatinum for malignant gliomas. Ophthalmology 1985; 92: 402-6.
23. Chrousos GA, Oldfield EH, Doppman JL, Cogan DG. Prevention of ocular toxicity of carmustine (BCNU) with supraophthalmic intracarotid infusion. Ophthalmology 1986; 93: 1471-5.
24. Clayman DA, Wolpert SM, Heros DO. Superselective arterial BCNU infusion in the treatment of patients with malignant gliomas. AJNR Am J Neuroradiol 1989; 10: 767-71.
25. Millay RH, Klein ML, Shults WT, Dahlborg SA, Neuwelt EA. Maculopathy associated with combination chemotherapy and osmotic opening of the blood-brain barrier. Am J Ophthalmol 1986; 102: 626-32.
26. Kemper EM, Boogerd W, Thuis I, Beijnen JH, van Tellingen O. Modulation of the blood-brain barrier in oncology: Therapeutic opportunities for the treatment of brain tumours? Cancer Treat Rev 2004; 30: 415-23.
27. Strauss O. The retinal pigment epithelium in visual function. Physiol Rev 2005; 85: 845-81.
28. Baich A, Ziegler M. The effect of sodium iodate and melanin on the formation of glyoxylate. Pigment Cell Res 1992; 5: 394-5.
29. Dasgupta P, Narayanaswami A. Glyoxylate aminotransferase activity in vertebrate retina. J Neurochem 1981; 37: 1603-6.
30. Leth PM, Gregersen M. Ethylene glycol poisoning. Forensic Sci Int 2005; 155: 179-84.
31. Klug S, Merker HJ, Jackh R. Effects of ethylene glycol and metabolites on in vitro development of rat embryos during organogenesis. Toxicol In Vitro 2001; 15: 635-42.
32. Poldelski V, Johnson A, Wright S, Rosa VD, Zager RA. Ethylene glycol-mediated tubular injury: Identification of critical metabolites and injury pathways. Am J Kidney Dis 2001; 38: 339-48.
33. Kiuchi K, Yoshizawa K, Shikata N, Moriguchi K, Tsubura A. Morphologic characteristics of retinal degeneration induced by sodium iodate in mice. Curr Eye Res 2002; 25: 373-9.
34. Heike M, Marmor MF. 1-cystein protects the pigment epithelium from acute sodium iodate toxicity. Doc Ophthalmol 1990; 75: 15-22.
35. Fujiwara Y, Sahashi Y, Aritro M et al. Effect of simultaneous administration of vitamin C, 1-cysteine and vitamin E on the melanogenesis. Biofactors 2004; 21: 415-18.
36. Rosenthal AR, Kolb H, Bergsma D, Huxsoll D, Hopkins JL. Chloroquine retinopathy in the rhesus monkey. Invest Ophthalmol Vis Sci 1978; 17: 1158-75.
37. Raines MF, Bhargava SK, Rosen ES. The blood-retinal barrier in chloroquine retinopathy. Invest Ophthalmol Vis Sci 1989; 30: 1726-31.
38. Mahon GJ, Anderson HR, Gardiner TA, McFarlane S, Archer DB, Stitt AW. Chloroquine causes lysosomal dysfunction in neural retina and RPE: implications for retinopathy. Curr Eye Res 2004; 28: 277-84.
39. Shichi H, Nebert DW. Genetic differences in drug metabolism associated with ocular toxicity. Environ Health Perspect 1982; 44: 107-17.
40. Olin KL, Morse LS, Murphy C et al. Trace element status and free radical defense in elderly rhesus macaques (Macaca mulatta) with macular drusen. Proc Soc Exp Biol Med 1995; 208: 370-7.
41. Shichi H, Tsunematsu Y, Nebert DW. Aryl hydrocarbon hydroxylase induction in retinal pigmented epithelium: Possible association of genetic differences in a drug-metabolizing enzyme system with retinal degeneration. Exp Eye Res 1976; 23: 165-76.
42. Patton WP, Routledge MN, Jones GD et al. Retinal pigment epithelial cell DNA is damaged by exposure to benzo[a]pyrene, a constituent of cigarette smoke. Exp Eye Res 2002; 74: 513-22.
43. Toler SM. Invited review: Fluphenazine augments retinal oxidative stress. J Ocul Pharmacol Ther 2005; 21: 259-65.
44. Potts A. Photosensitizing substances. In: Sears M, ed. Photosensitizing Substances, Vol. 69. Heidelberg: Springer-Verlag, 1984; 655-65.
45. Tate DJ Jr, Miceli MV, Newsome DA. Phagocytosis and H2O2 induce catalase and metallothionein gene expression in human retinal pigment epithelial cells. Invest Ophthalmol Vis Sci 1995; 36: 1271-9.
46. Roberts JE. Ocular phototoxicity. J Photochem Photobiol B 2001; 64: 136-43.
47. Algvere PV, Marshall J, Seregard S. Age-related maculopathy and the impact of blue light hazard. Acta Ophthalmol Scand 2006; 84: 4-15.
48. Yildirim O, Ates NA, Tamer L et al. Changes in antioxidant enzyme activity and malondialdehyde level in patients with age-related macular degeneration. Ophthalmologica 2004; 218: 202-6.
49. Organisciak DT, Wang HM, Kou AL. Ascorbate and glutathione levels in the developing normal and dystrophic rat retina: Effect of intense light exposure. Curr Eye Res 1984; 3: 257-67.
50. Roberts JE. Screening for ocular phototoxicity. Int J Toxicol 2002; 21: 491-500.
51. Reme C, Reinboth J, Clausen M, Hafezi F. Light damage revisited: converging evidence, diverging views? Graefes Arch Clin Exp Ophthalmol 1996; 234: 2-11.
52. Glickman RD. Phototoxicity to the retina: Mechanisms of damage. Int J Toxicol 2002; 21: 473-90.
53. Mauget-Faysse M, Quaranta M, Francoz N, BenEzra D. Incidental retinal phototoxicity associated with ingestion of photosensitizing drugs. Graefes Arch Clin Exp Ophthalmol 2001; 239: 501-8.
54. Wang RH, Dillon J, Reme C, Whitt R, Roberts JE. The potential ocular phototoxicity of antidepressant drugs. Lens Eye Toxic Res 1992; 9: 483-91.
55. Yip HK, Lai TY, So KF, Kwok AK. Retinal ganglion cells toxicity caused by photosensitising effects of intravitreal indocyanine green with illumination in rat eyes. Br J Ophthalmol 2006; 90: 99-102.
56. Power WJ, Travers SP, Mooney DJ. Welding arc maculopathy and fluphenazine. Br J Ophthalmol 1991; 75: 433-5.
57. Seddon JM, George S, Rosner B. Cigarette smoking, fish consumption, omega-3 fatty acid intake, and associations with age-related macular degeneration: The US Twin Study of Age-related Macular Degeneration. Arch Ophthalmol 2006; 124: 995-1001.
58. Clemons TE, Milton RC, Klein R, Seddon JM, Ferris FL, 6 rd. Risk factors for the incidence of Advanced Age-Related Macular Degeneration in the Age-Related Eye Disease Study (AREDS) AREDS report, 19. Ophthalmology 2005; 112: 533-9.
59. Vingerling JR, Hofman A, Grobbee DE, de Jong PT. Age-related macular degeneration and smoking. The Rotterdam Study. Arch Ophthalmol 1996; 114: 1193-6.
60. McCusker K, Hoidal J. Selective increase of antioxidant enzyme activity in the alveolar macrophages from cigarette smokers and smoke-exposed hamsters. Am Rev Respir Dis 1990; 141: 678-82.
61. Espinosa-Heidmann DG, Suner IJ, Catanuto P, Hernandez EP, Marin-Castano ME, Cousins SW. Cigarette smoke-related oxidants and the development of sub-RPE deposits in an experimental animal model of dry AMD. Invest Ophthalmol Vis Sci 2006; 47: 729-37.
62. Hafezi F, Marti A, Munz K, Reme CE. Light-induced apoptosis: differential timing in the retina and pigment epithelium. Exp Eye Res 1997; 64: 963-70.
63. Abler AS, Chang CJ, Ful J, Tso MO, Lam TT. Photic injury triggers apoptosis of photoreceptor cells. Res Commun Mol Pathol Pharmacol 1996; 92: 177-89.
64. Grimm C, Wenzel A, Hafezi F, Yu S, Redmond TM, Reme CE. Protection of Rpe65-deficient mice identifies rhodopsin as a mediator of light-induced retinal degeneration. Nat Genet 2000; 25: 63-6.
65. Wenzel A, Grimm C, Samardzija M, Reme CE. The genetic modifier Rpe65Leu (450): Effect on light damage susceptibility in c-Fos-deficient mice. Invest Ophthalmol Vis Sci 2003; 44: 2798-802.
66. Williams TP. Photoreversal of Rhodopsin bleaching. J Gen Physiol 1964; 47: 679-89.
67. Grimm C, Wenzel A, Williams T, Rol P, Hafezi F, Reme C. Rhodopsin-mediated blue-light damage to the rat retina: Effect of photoreversal of bleaching. Invest Ophthalmol Vis Sci 2001; 42: 497-505.
68. Dunaief JL, Dentchev T, Ying GS, Milam AH. The role of apoptosis in age-related macular degeneration. Arch Ophthalmol 2002; 120: 1435-42.
69. Xu GZ, Li WW, Tso MO. Apoptosis in human retinal degenerations. Trans Am Ophthalmol Soc 1996; 94: 411-30; discussion 30-1.
70. Mainster MA. Violet and blue light blocking intraocular lenses: photoprotection versus photoreception. Br J Ophthalmol 2006; 90: 784-92.
71. Cruickshanks KJ, Klein R, Klein BE, Nondahl DM. Sunlight and the 5-year incidence of early age-related maculopathy: The beaver dam eye study. Arch Ophthalmol 2001; 119: 246-50.
72. Mitchell P, Wang JJ, Foran S, Smith W. Five-year incidence of age-related maculopathy lesions: The Blue Mountains Eye Study. Ophthalmology 2002; 109: 1092-7.
73. Wang JJ, Mitchell PG, Cumming RG, Lim R. Cataract and age-related maculopathy: The Blue Mountains Eye Study. Ophthalmic Epidemiol 1999; 6: 317-26.
74. Wang JJ, Klein R, Smith W, Klein BE, Tomany S, Mitchell P. Cataract surgery and the 5-year incidence of late-stage age-related maculopathy: pooled findings from the Beaver Dam and Blue Mountains eye studies. Ophthalmology 2003; 110: 1960-7.
75. Nilsson SE. Are there advantages in implanting a yellow IOL to reduce the risk of AMD? Acta Ophthalmol Scand 2004; 82: 123-5.
76. Mainster MA. Intraocular lenses should block UV radiation and violet but not blue light. Arch Ophthalmol 2005; 123: 550-5.
77. Braunstein RE, Sparrow JR. A blue-blocking intraocular lens should be used in cataract surgery. Arch Ophthalmol 2005; 123: 547-9.
78. Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report, 8. Arch Ophthalmol 2001; 119: 1417-36.
79. Evans JR. Antioxidant vitamin and mineral supplements for slowing the progression of age-related macular degeneration. Cochrane Database Syst Rev 2006; Issue 2: Art No: CD000254. DOI: 10.1002/14651858.CD000254.pub2.